Avista Therapeutics, a preclinical-stage biotechnology company focused on developing innovative gene therapies for rare ophthalmic conditions, has announced a strategic partnership with Forge Biologics, a leading contract development and manufacturing organization (CDMO) for genetic medicines. This collaboration is a critical step in advancing AVST-101, Avista's lead gene therapy candidate for X-linked retinoschisis (XLRS), a severe inherited retinal disease that leads to progressive vision loss, primarily in males. Currently, there is no approved treatment for this condition, making the development of AVST-101 a high-priority effort.
The partnership leverages the unique strengths of both companies. Avista brings to the table its computationally guided scAAVengr platform, which enables the creation of proprietary adeno-associated virus (AAV) vectors designed for highly targeted and efficient gene delivery. This technology is at the heart of AVST-101, which aims to provide a more accessible and safer treatment option by utilizing a next-generation AAV capsid for low-dose, intravitreal delivery and broad retinal coverage. The intravitreal delivery method is less invasive than subretinal injections, potentially broadening the patient population and improving the overall treatment experience.
Forge Biologics, a member of the Ajinomoto Bio-Pharma Services group, will serve as the manufacturing partner. Avista will utilize Forge's proprietary FUEL™ platform, which is an advanced AAV manufacturing solution designed to increase yields, improve scalability, and enhance efficiency. Forge will provide a comprehensive suite of services from its state-of-the-art 200,000 square foot facility in Columbus, Ohio, known as the Hearth. These services include process development, current Good Manufacturing Practices (cGMP) manufacturing, toxicology, and analytical development. By utilizing Forge's established manufacturing processes and proprietary technologies, such as its Ignition Cells™ and pEMBR™ 2.0 adenovirus helper plasmid, Avista can streamline its development pathway, ensuring the speed, consistency, and quality necessary to bring AVST-101 to patients with urgent needs.
The collaboration represents a significant milestone for Avista, as it secures a reliable and expert manufacturing partner to transition its promising preclinical candidate into clinical development. For Forge, this partnership aligns with its mission to help accelerate the delivery of life-changing gene therapies. The successful development of AVST-101 could not only provide the first-ever treatment for XLRS but also validate Avista’s broader platform for developing gene therapies for other rare ophthalmic diseases, offering hope to many patients facing vision loss.